CD79B and neoplasm: Wilson et al. reported that the median PFS was longer in ABC-DLBCL; the ORR in patients with CD79B mutations was higher than that in those with wild type; there was no significant difference between tumours with MYD88 mutations and those with wild type; tumours with both CD79B and MYD88 mutations were more responsive than those with CD79 wild-type and MYD88 mutations among ABC-DLBCL [94].